Arcutis Biotherapeutics (ARQT) Net Cash Flow (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Net Cash Flow of -$8.0 million for Q1 2026, up 55.99% year-over-year from -$5.1 million in Q1 2025, and down 87.87% quarter-over-quarter from -$4.3 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Net Cash Flow (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$8.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 55.99% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$18.7 million (up 86.34% YoY), while the FY2025 annual figure was -$28.9 million, down 68.68% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$8.0 million, down from -$4.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $101.5 million in Q1 2024, with the low at -$105.8 million in Q2 2024.
- The 5-year median for Net Cash Flow is -$8.0 million (2026), against an average of -$3.7 million.
- Peak annual rise in Net Cash Flow reached 1975.78% in 2024, while the deepest fall reached 546.42% in 2024.
- Arcutis Biotherapeutics' Net Cash Flow stood at -$27.9 million in 2022, then jumped by 31.4% to -$19.1 million in 2023, then plunged by 230.61% to -$63.3 million in 2024, then surged by 93.25% to -$4.3 million in 2025, then plunged by 87.87% to -$8.0 million in 2026.
- Business Quant data shows ARQT's Net Cash Flow at -$8.0 million in Q1 2026, -$4.3 million in Q4 2025, and -$25.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | -595,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -595,000.00 |
| Jun 30, 2026 | -595,000.00 |
| Mar 31, 2026 | -8.03 Mn |
| Mar 31, 2026 | -8.03 Mn |
| Dec 31, 2025 | -4.27 Mn |
| Dec 31, 2025 | -4.27 Mn |
| Sep 30, 2025 | -25.53 Mn |
| Sep 30, 2025 | -25.53 Mn |
| Jun 30, 2025 | 19.13 Mn |
| Jun 30, 2025 | 19.13 Mn |
| Mar 31, 2025 | -18.24 Mn |
| Mar 31, 2025 | -18.24 Mn |
| Dec 31, 2024 | -63.28 Mn |
| Dec 31, 2024 | -63.28 Mn |
| Sep 30, 2024 | 50.48 Mn |
| Sep 30, 2024 | 50.48 Mn |
| Jun 30, 2024 | -105.80 Mn |
| Jun 30, 2024 | -105.80 Mn |
| Mar 31, 2024 | 101.46 Mn |
| Mar 31, 2024 | 101.46 Mn |